News

Bayer partners with KeyGene
Enlarge image

BusinessGermanyNetherlands

Bayer partners with KeyGene

24.04.2013 - Bayer Crop Science has entered a multi-year R&D partnership with Keygene to improve traits in crops.

The German and the Dutch company announced that the scope of their first research programme is wheat, potentially to be followed by projects in oilseed rape, rice and cotton. In the collaboration, Bayer will access KeyGene’s KeySeeQ® discovery pipeline. The platform technology will be used to identify genes associated with novel traits such as drought tolerance. The genes will be then improved by KeyGene using its automated high throughput targeted mutagenesis tool KeyPoint®. Bayer will be responsible for global market introduction of the resulting new wheat varieties.

“Bayer has the goal to offer farmers tailor-made wheat varieties with improved yield and other agronomically-important traits including drought tolerance and nitrogen use efficiency,” said David Nicholson, Global R&D Head at Bayer CropScience. However, it's not an easy task to create new varieties in wheat due to its polyploidy and the involvement of many genes in such complex traits such as drought tolerance.   However, improving the tolerance of wheat varieties to cope with drought and other environmental stress factors is important across the world.

Wheat is one of the most important staple crops for humans: the worldwide consumption was 704 million tons in 2011. It is expected that by 2030 farmers will face an increase of 40% in the world-wide demand for wheat. Therefore, new varieties need to provide farmers with important agricultural innovations which help them to sustainably increase yield and profitability.

© eurobiotechnews.eu/tg

BusinessGermanyFrance

15.04.2014 German flavour and scent specialist Symrise has announced its plans to acquire French pet-food ingredients maker Diana Group for €1.3bn.

BioeconomySpain

14.04.2014 Spanish Neol Biosolutions and the Center for Second Generation Biofuels are starting a partnership to scale-up Neol's waste-to-oil technology.

EvidenceUKSwitzerland

11.04.2014 There is no evidence that neuraminidase inhibitors Tamiflu and Relenza prevent complications of influenza or reduce hospital admissions. In addition, it is unclear whether they can stop the spread of influenza in case of outbreaks, says a report by the Cochrane Collaboration.

BusinessSwitzerlandSpain

09.04.2014 Roche is extending its involvement in the area of point-of-care diagnostics by taking over US company Iquum. In the field of epigenetics, the Swiss pharma company has started a cooperation with the Spanish company Oryzon.

Status ReportSwitzerland

08.04.2014 The Swiss Biotech Report 2014 presented in Zurich sees an encouraging upturn in the country's biotech scene. However, the acceptance of the mass immigration initiative poses a significant threat.

NanobiotechnologyItaly

07.04.2014 Scientists from the University of Udine have designed, produced and tested a prototype for a "DNA origami" nanorobot that can potentially deliver biological activators in-vivo.

EpidemicEUFranceGermanyItaly

02.04.2014 As the Ebola epidemic in Guinea worsens, Europe is deploying the specialists of EMLab to provide diagnostics at the focus of the outbreak.

BioeconomyFranceEU

01.04.2014 The European Commission has approved a French state package aid worth €43m for green chemistry project IEED.

MonitoringEU

27.03.2014 In Europe, bacterial resistance to prevalent antimicrobials is common, while multi-resistance remains low, EFSA and ECDC now report.

FinancingFrance

25.03.2014 Immunotherapy developer Transgene SA has successfully raised a total of €65.5m via a two-step capital increase – including a rights issue and a private placement.

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CYTOS (CH)0.23 CHF53.3%
  • BAVARIAN NORDIC (D)14.56 EUR10.3%
  • CO.DON (D)3.40 EUR9.7%

FLOP

  • WILEX (D)0.88 EUR-15.4%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • FLAMEL TECHNOLOGIES (F)11.01 USD-13.5%

TOP

  • CO.DON (D)3.40 EUR94.3%
  • BIOTECH PHARMACON (N)17.50 NOK59.1%
  • WILEX (D)0.88 EUR44.3%

FLOP

  • CYTOS (CH)0.23 CHF-92.0%
  • BIONOR PHARMA (N)2.11 NOK-49.0%
  • GW PHARMACEUTICALS (UK)219.50 GBP-39.5%

TOP

  • SILENCE THERAPEUTICS (UK)255.00 GBP6119.5%
  • IXICO (UK)69.50 GBP782.0%
  • PLETHORA (UK)11.00 GBP609.7%

FLOP

  • CYTOS (CH)0.23 CHF-94.4%
  • EVOCUTIS (UK)0.22 GBP-92.7%
  • AGENNIX (D)0.04 EUR-80.0%

No liability assumed, Date: 16.04.2014